Sexual dysfunction following radical prostatectomy

Journal of Andrology

Volumn 33, Issue 6, 2012, Pages 1143-1154

  Benson, Cooper R ^a   Serefoglu, Ege Can ^b   Hellstrom, Wayne J G ^b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dysorgasmia; Erectile dysfunction; Penile rehabilitation; Penile shortening; Peyronie disease

Indexed keywords

CANCER MORTALITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HUMAN; LIBIDO DISORDER; MEDICAL LITERATURE; ORGASM DISORDER; PEYRONIE DISEASE; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION;

ALPROSTADIL; ANIMALS; ERECTILE DYSFUNCTION; HUMANS; LIBIDO; MALE; MIDDLE AGED; PENILE INDURATION; PENIS; PIPERAZINES; PROSTATECTOMY; PROSTATIC NEOPLASMS; PURINES; QUALITY OF LIFE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SULFONES;

EID: 84874412337     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.112.016790     Document Type: Review

References (124)

1. Ahlering TE, Rodriguez E, Skarecky DW. Impact of cautery versus cautery-free preservation of neurovascular bundles on early return of potency. J Endourol. 2006;22:745-750.
2. Albaugh J, Ferrans C. Impact of penile injections on men with erectile dysfunction after prostatectomy. Urol Nurs. 2010;30:74-77.
3. Alemozaffar M, Regan M, Cooperberg M, Wei J, Michalski J, Sandler H, Hembroff L, Sadetsky N, Saigal C, Litwin M, Klein E, Kibel A, Hamstra D, Pisters L, Kuban D, Kaplan I, Wood D, Ciezki J, Dunn R, Carroll P, Sanda M. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011;306:1205-1214.
4. Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol. 2005;174:2060-2064.
5. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
6. Bakircioglu ME, Lin CS, Fan P, Sievert KD, Kan YW, Lue TF. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol. 2001;165:2103-2109.
7. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Junemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008;101:1279-1283.
8. Bannowsky A, Schulze H, van der Horst C, Junemann KP. Nervesparing radical prostatectomy with nightly low-dose sildenafil: rehabilitation of erectile function. Urologe A. 2010;49:1516-1521.
9. Barnas J, Parker M, Guhring P, Mulhall JP. The utility of tamsulosin in the management of orgasm-associated pain: a pilot study. Eur Urol. 2005;47:361-365.
10. Barnas J, Pierpaoli S, Ladd P, Valenzuela R, Aviv N, Parker M, Waters WB, Flanigan RC, Mulhall JP. The prevalence and nature of orgasmic dysfunction after radical prostatectomy. BJU Int. 2004;94:603-605.
11. Bates TS, Wright MP, Gillatt DA. Prevalence and impact of incontinence and impotence following total prostatectomy assessed anonymously by the ICS-male questionnaire. Eur Urol. 1998;33: 165-169.
12. Bill-Axelson A, Holmberg L, Ruutu M, Häggman M, Andersson S-O, Bratell S, Spångberg A, Busch C, Nordling S, Garmo H, Palmgren J, Adami H-O, Norlén BJ, Johansson J-E. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352:1977-1984.
13. Breza J, Abosief SR, Orvis BR, Lue TF, Tanago EA. Detailed anatomy of penile neurovascular structures surgical significance. J Urol. 1989;141:437-443.
14. Bronner G, Shefi S, Raviv G. Sexual dysfunction after radical prostatectomy: treatment failure or treatment delay? J Sex Marital Ther. 2010;36:421-429.
15. Burnett AL. Novel nitric oxide signaling mechanisms regulate the erectile response. Int J Impot Res. 2004;16:S15-S19.
16. Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005;293:2648-2653.
17. Burnett AL, Allaf ME, Bivalacqua TJ. Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis. J Sex Med. 2008;5:2392-2398.
18. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science. 1992; 257:401-403.
19. Carrier S, Zvara P, Nunes L, Kour NW, Rehman J, Lut TF. Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol. 1995;153:1722-1727.
20. Chen J, Godschalk MF, Katz PG, Mulligan T. Combining intracavernous injection and external vacuum as treatment for erectile dysfunction. J Urol. 1995;153:1476-1477.
21. Choi JM, Nelson CJ, Stasi J, Mulhall JP. Orgasm associated incontinence (climacturia) following radical pelvic surgery; rates of occurrence and predictors. J Urol. 2007;177(6):2223-2226.
22. Ciancio SJ, Kim ED. Penile fibrotic changes after radical retropubic prostatectomy. BJU Int. 2000;85(1):101-106.
23. Costabile RA, Spevak M, Fishman IJ, Govier FE, Hellstrom WJ, Shabsigh R, Nemo KJ, Rapport JL, Tam PY, Weldon KL, Gesundheit N. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol. 1998;160:1325-1328.
24. Dahn JR, Penedo FJ, Gonzalez JS, Esquiabro M, Antoni MH, Roos BA, Schneiderman N. Sexual functioning and quality of life after prostate cancer treatment: considering sexual desire. Urology. 2004; 63:273-277.
25. Daley JT, Watkins MT, Brown ML, Martinez V, Cuevas P, Saenz de Tajada I. Protanoid production in rabbit corpus cavernosum. II. Inhibition by oxidative stress. J Urol. 1996;156:1169-1173.
26. Davis JW, Chang DW, Chevray P, Wang R, Shen Y, Wen S, Pettaway CA, Pisters LL, Swanson DA, Madsen LT, Huber N, Troncoso P, Babaian RJ, Wood CG. Randomized phase II trial evaluation of erectile function after attempted unilateral cavernous nerve-sparing retropubic radical prostatectomy with versus without unilateral sural nerve grafting for clinically localized prostate cancer. Eur Urol. 2009;55:1135-1144.
27. Dean RC, Lue TF. Neuroregenerative strategies after radical prostatectomy. Rev Urol. 2005a;7(Suppl 2):S26-S32.
28. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005b;32:379-395,v.
29. DeFade B, Carson C, Kennelly M. Postprostatectomy erectile dysfunction: the role of penile rehabilitation. Rev Urol. 2011;13:6-13.
30. Dennis RL, McDougal WS. Pharmacological treatment of erectile dysfunction after radical prostatectomy. J Urol. 1988;139:775-776.
31. Droller MJ, Anderson JR, Beck JC, Bremner WJ, Evans K, Gray M, Keeney AH, Lanzisera PJ, Liao WC, Richardson DW, Rohner TJ Jr, Shortliffe LD, Turner WR, Zitrin A. Impotence. NIH Consens Statement Online. 1992;10(4):1-31.
32. Droupy S, Hessel A, Benoit G, Blanchet P, Jardin A, Giuliano F. Assessment of the functional role of accessory pudendal arteries in erection by transrectal Doppler ultrasound. J Urol. 1999;162: 1987-1991.
33. Dubbelman Y, Dohle G, Schroder F. Sexual function before and after radical retropubic prostatectomy: a systematic review of prognostic indicators for a successful outcome. Eur Urol. 2006;50:711-720.
34. Dubbelman Y, Wildhagen M, Schroder F, Bangma C, Dohle G. Orgasmic dysfunction after open radical prostatectomy: clinical correlates and prognostic factors. J Sex Med. 2010;7:1216-1223.
35. Dwyer M, Nehra A. Defining sexual function after radical retropubic prostatectomy. Urol Oncol. 2010;28:469-472.
36. Ferrini M, Davila H, Kovanecz I, Sanchez S, Gonzalez-Cadavid N, Rajfer J. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology. 2006;68:429-435.
37. Ferrini M, Kovanecz I, Sanchez S, Umeh C, Rajfer J, Gonzalez-Cadavid N. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (cvod) induced by experimental cavernosal nerve damage in the rat. J Sex Med. 2009;6:415-428.
38. Filippi S, Marini M, Vannelli GB, Crescioli C, Granchi S, Vignozzi L, Luconi M, Ferruzzi P, Morelli A, Forti G, Ledda F, Maggi M. Effects of hypoxia on endothelin-1 sensitivity in the corpus cavernosum. Mol Hum Reprod. 2003;9:765-774.
39. Foresta C, De Toni L, Di Mambro A, Garolla A, Ferlin A, Zuccarello D. The PDE5 inhibitor sildenafil increases circulating endothelial progenitor cells andCXCR4 expression. J Sex Med. 2009;6:369-372.
40. Fraiman M, Lepor H, McCullough A. Changes in penile morphometrics in men with erectile dysfunction after nerve sparing radical retropubic prostatectomy. Mol Urol. 1999;3:109-115.
41. Garcia F, Brock G. Current state of penile rehabilitation after radical prostatectomy. Curr Opin Urol. 2010;20:234-240.
42. Gontero P, Fontana F, Bagnasacco A, Panella M, Kocjancic E, Pretti G, Frea B. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol. 2003;169:2166-2169.
43. Gontero P, Galzerano M, Bartoletti R, Magnani C, Tizzani A, Frea B, Mondaini N. New insights into pathogenesis of penile shortening after radical prostatectomy and the role of postoperative sexual function. J Urol. 2007;178:602-607.
44. Hatzimouratidis K, Burnett AL, Hatzichristou D, McCullough AR, Montorsi F, Mulhall JP. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol. 2009; 55:334-347.
45. Hoffman R. Screening for prostate cancer. N Engl J Med. 2011; 365:2013-2019.
46. Hu JC, Gu X, Lipsitz SR, Barry MJ, D'Amico AV, Weinberg AC, Keating NL. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302:1557-1564.
47. Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol. 2005;173:1673-1676.
48. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460-463.
49. Kandeel F, Koussa V, Swerdloff R. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocrine Rev. 2001;22:342-388.
50. Kato R, Wolfe D, Coyle CH, Huang S, Wechuck JB, Goins WF, Krisky DM, Tsukamoto T, Nelson JB, Glorioso JC, Chancellow MB, Yoshimura N. Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther. 2007;14:1344-1352.
51. Kawanishi Y, Lee KS, Kimura K, Kojima K, Yamamoto A, Numata A. Effect of radical retropubic prostatectomy on erectile function, evaluated before and after surgery using color Doppler ultrasonography and nocturnal penile tumescence monitoring. BJU Int. 2001;88:244-247.
52. Khoudary KP, DeWolf WC, Bruning CO 3rd, Morgentaler A. Immediate sexual rehabilitation by simultaneous placement of penile prosthesis in patients undergoing radical prostatectomy: initial results in 50 patients. Urology. 1997;50:395-399.
53. Kim ED, Nath R, Slawin KM, Kadmon D, Miles BJ, Scardino PT. Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology. 2001;58:983-987.
54. Kim S, Song C, Kim W, Kang T, Park J, Jeong I, Lee S, Cho Y, Ahn H. Factors determining functional outcomes after radical prostatectomy: robot-assisted versus retropubic. Euro Urol. 2011;60:413-419.
55. Klein LT, Miller MI, Buttyan R, Raffo AJ, Burchard M, Devris G, Cao YC, Olsson C, Shabsigh R. Apoptosis in the rat penis after penile denervation. J Urol. 1997;158:626-630.
56. Ko W, Degner L, Hack T, Schroeder G. Penile length shortening after radical prostatectomy: men's responses. Eur J Oncol Nurs. 2010; 14:160-165.
57. Kohler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, Makhlouf A, Ryndin I, Canales BK, Weiland D, Nakib N, Ramani A, Anderson JK, Monga M. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 2007;100:858-862.
58. Lagoda G, Sezen SF, Burnett AL. FK506 and rapamycin neuroprotect erection and involve different immunophilins in a rat model of cavernous nerve injury. J Sex Med. 2009;6:1914-1923.
59. Lagoda G, Xie Y, Sezen SF, Hurt KJ, Liu L, Musicki B, Burnett AL. FK506 neuroprotection after cavernous nerve injury is mediated by thioredoxin and glutathione redox systems. J Sex Med. 2011; 8:3325-3334.
60. Laumann E, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281:537-544.
61. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR; CaPSURE Investigators. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010;106:1022-1029.
62. Lee J, Hersey K, Lee C, Fleshner N. Climacturia following radical prostatectomy: prevalence and risk factors. J Urol. 2006;176: 2562-2565.
63. Leungwattanakij S, Bivalacqua T, Usta M, Yang D, Hyun J, Champion H, Abdel-Mageed A, Hellstrom W. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl. 2003;24:239-245.
64. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol. 1998;159:1988-1992.
65. Liu T, AllafME, LagodaG, BurnettAL. Erythropoietin receptor expression in the human urogenital tract: immunolocalization in the prostate, neurovascular bundle and penis. BJU Int. 2007;100:1103-1106.
66. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802-1813.
67. Lysiak JJ, Yang S-K, Klausner AP, Son H, Tuttle JB, Steers WD. Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. J Urol. 2008;179:779-785.
68. Magelssen H, Brydoy M, Fossa S. The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract Urol. 2006;3:312-322.
69. Martínez-Salamanca J, Marti{dotless}́nez-Ballesteros C, Portillo I, Moncada L, Carballido J. Penile morphometric changes after radical prostatectomy: evidence-based [in Spanish]. Actas Urol Esp. 2010;34:579-585.
70. Matsushita K, Tal R, Mulhall JP. The evolution of orgasmic pain (dysorgasmia) following radical prostatectomy. J Sex Med. 2012; 9:1454-1458.
71. McCullough AR. Prevention and management of erectile dysfunction following radical prostatectomy. Urol Clin North Am. 2001;28: 613-627.
72. McCullough AR. Rehabilitation of erectile function following radical prostatectomy. Asian J Androl. 2008;10:61-74.
73. McCullough AR, Levine LA, Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated with nightly sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebocontrolled trial. J Sex Med. 2007;5:476-484.
74. Meyer J, Gillatt D, Lockyer R, Macdonagh R. The effect of erectile dysfunction on the quality of life of men after radical prostatectomy. BJU Int. 2003;92:929-931.
75. Montorsi F, Briganti A, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol. 2004a;45:123-133.
76. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, Stief C. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924-931.
77. Montorsi F, Guazzoni G, Strambi L, Da Pozzo L, Nava L, Barbieri L, Rigatti P, Pizzini G, Miani A. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997;158:1408-1410.
78. Montorsi F, Nathan HP, McCullough A, Brock GB, Broderick G, Ahuja S, Whitaker S, Hoover A, Novack D, Murphy A, Varanese L. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004b;172:1036-1041.
79. Moreland RB. Is there a role of hypoxemia in penile fibrosis: A viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10:113-120.
80. Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tajada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol. 1995;153(3 Pt 1):826-834.
81. Mulhall JP. Penile length changes after radical prostatectomy. BJU Int. 2005;96:472-474.
82. Mulhall JP. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol. 2009;181:462-471.
83. Mulhall JP, Bella AJ, Briganti A, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med. 2010;7:1687-1698.
84. Mulhall JP, Land S, Parker M, Waters WB, Flanigan RC. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005;2:532-554.
85. Mulhall JP, Muller A, Donohue JF, Mullerad M, Kobylarz K, Paduch DA, Tal R, Li PS, Cohen-Gould L, Scardino PT. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med. 2008;5: 1126-1136.
86. Mulhall JP, Slovick R, Hotaling J, Aviv N, Valenzuela R, Waters WB, Flanigan RC. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol. 2002;167:1371-1375.
87. Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol. 2005;68:226-232.
88. Mydlo JH, Viterbo R, Crispen P. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with suboptimal response to sildenafil and/or vardenafil monotherapy after radical prostatectomy. BJU Int. 2005;95:843-846.
89. Nandipati K, Raina R, Agarwal A, Zippe CD. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. 2006;18:446-451.
90. Nehra A, Grantmyre J, Nadel A, Thibonnier M, Brock G. Vardenafil improved patient satisfaction with erectile hardness, orgasmic function and sexual experience in men with erectile dysfunction following nervesparing radical prostatectomy. J Urol. 2005;173:2067-2071.
91. Nilsson AE, Carlsson S, Johansson E, Jonsson MN, Adding C, Nyberg T, Steineck G, Wiklund NP. Orgasm-associated urinary incontinence and sexual life after radical prostatectomy. J Sex Med. 2011;8:2632-2639.
92. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, Giuliano F, Brock G. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nervesparing radical prostatectomy. Int J Impot Res. 2008;20:479-486.
93. Pahlajani G, Raina R, Jones S, Ali M, Zippe CD. Vacuum erection devices revisited: its emerging role in the treatment of erectile dysfunction and early penile rehabilitation following prostate cancer therapy. J Sex Med. 2012;9:1182-1189.
94. Patel V, Abdul-Muhsin H, Schatloff O, Coelho R, Valero R, Ko Y, Sivaraman A, Palmer K, Chauhan S. Critical review of 'pentafecta' outcomes after robot-assisted laparoscopic prostatectomy in highvolume centres. BJU Int. 2011;108:1007-1017.
95. Penson D, Latini D, Lubeck D, Wallace K, Henning J, Lue T. Is quality of life different for men with erectile dysfunction and prostate cancer compared to men with erectile dysfunction due to other causes? Results from the Exceed database. J Urol. 2003;169: 1458-1461.
96. Penson DF. The effect of erectile dysfunction on quality of life following treatment for localized prostate cancer. Rev Urol. 2001;3:113-119.
97. Perez MA, Meyerowitz BE, Lieskovsky G, Skinner DG, Reynolds B, Skinner EC. Quality of life and sexuality following radical prostatectomy in patients with prostate cancer who use or do not use erectile aids. Urology. 1997;50:740-746.
98. Perez MA, Skinner EC, Meyerowitz BE. Sexuality and intimacy following radical prostatectomy: patient and partner perspectives. Health Psychol. 2002;21:288-293.
99. Raina R, Lakin MM, Thukral M, Agarwal A, Ausmundson S, Montague DK, Klein E, Zippe CD. Long-term efficacy and compliance of intracorporeal (IC) injection for erectile dysfunction following radical prostatectomy:SHIM(IIEF-5) analysis. Int J Impot Res. 2003;15:318-322.
100. Raina R, Agarwal A, Allamaneni SS, Lakin MM, Zippe CD. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology. 2005a;65:360-364.
101. Raina R, Agarwal A, Zaramo CE, Ausmundson S, Mansour D, Zippe CD. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis. Int J Impot Res. 2005b;17:86-90.
102. Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati KC, Montague DK, Mansour D, Zippe CD. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res. 2006;18:77-81.
103. Raina R, Pahlajani G, Agarwal A, Zippe CD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 2007;100:1317-1321.
104. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic noncholinergic neurotransmission. N Engl J Med. 1992;326:90-94.
105. Ramsawh H, Morgentaler A, Covino N, Barlow D, DeWolf W. Quality of life following simultaneous placement of penile prosthesis with radical prostatectomy. J Urol. 2005;174:1395-1398.
106. Rogers CG, Trock BP, Walsh PC. Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. Urology. 2004;64:148-151.
107. Ruiz Rubio JL, Hernandez M, Rivera de los Arcos L, Martinez AC, Garcia-Sacristan A, Prieto D. Mechanisms of prostaglandin E1-induced relaxation in penile resistance arteries. J Urol. 2004;171:968-973.
108. Sattar AA, Salpigides G, Vanderhaeghen JJ, Schulam CC, Wespes E. Cavernous oxygen tension and smooth muscle fibers: relation and function. J Urol. 1995;154:1736-1739.
109. Savoie M, Kim S, Soloway M. A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol. 2003;169:1462-1464.
110. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004;171:771-774.
111. Segal R, Burnett A. Erectile preservation following radical prostatectomy. Ther Adv Urol. 2011;3:35-46.
112. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol. 2001;165:430-435.
113. Sighinolfi MC, Rivalta M, Mofferdin A, Micali S, De Stefani S, Bianchi G. Potential effectiveness of pelvic floor rehabilitation treatment for postradical prostatectomy incontinence, climacturia, and erectile dysfunction: a case series. J Sex Med. 2009;6:3496-3499.
114. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rhokinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol. 2000;522(Pt 2):177-185.
115. Tal R, Heck M, Teloken P, Siegrist T, Nelson C, Mulhall JP. Peyronie's disease following radical retropubic prostatectomy: incidence and predictors. J Sex Med. 2010;7:1254-1261.
116. Tewari A, Grover S, Sooriakumaran P, Srivastava A, Rao S, Gupta A, Gray R, Leung R, Paduch D. Nerve sparing can preserve orgasmic function in most men after robot-assisted laparoscopic radical prostatectomy. BJU Int. 2011;4:596-602.
117. Treiyer A, Anheuser P, Butow Z, Steffens J. A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy. J Urol. 2011;185:1681-1685.
118. Tsivian M, Mayes J, Krupski T, Mouraviev V, Donatucci C, Polascik T. Altered male physiologic function after surgery for prostate cancer: couple perspective. Int Braz J Urol. 2009;35:673-682.
119. User H, Hairston J, Zelner D, McKenna K, McVary K. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol. 2003;169:1175-1179.
120. Walsh P, Lepor H, Eggleston J. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4:473-485.
121. Walz J, Burnett AL, Costello AJ, Eastham JA, Graefen M, Guillonneau B, Menon M, Montorsi F, Myers RP, Rocco B, Villers A. A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol. 2010;57:179-192.
122. 2+ sensitization in erectile function. J Biol Chem. 2002;277:30614-30621.
123. Wang R. Penile rehabilitation after radical prostatectomy: where do we stand and where are we going? J Sex Med. 2007;4:1085-1097.
124. Zhou S, Chen LS, Miyauchi M, Kar S, Kangavari S, Fishbein MC, Sharifi MC, Chen PS. Mechanisms of cardiac nerve sprouting after myocardial infarction in dogs. Circ Res. 2004;95:76-83.